Sugi Predict

Sugi Predict / Compounds / SCHEMBL8287368

SCHEMBL8287368

SCHEMBL8287368

COC[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 2/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA7 P43166 1/20 0.50
▸ CYP2D6 P10635 1/20 0.45
▸ CTSK P43235 11/20 0.43
▸ CTSS P25774 6/20 0.43
▸ CTSL P07711 2/20 0.38
▸ CTSB P07858 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ SYK P43405 1/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA14 Q9ULX7 1/20 0.37
▸ APLNR P35414 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23924579 1.00 CA2 (0.50) CA2CA1CA7CYP2D6CTSK
SCHEMBL1371767 1.00 CA2 (0.50) CA2CA1CA7CYP2D6CTSK
SCHEMBL90583 0.82 CA1 (0.47) CA2CA1CA7CYP2D6CTSK
SCHEMBL89997 0.82 CA1 (0.47) CA2CA1CA7CYP2D6CTSK
SCHEMBL23924557 0.82 CA1 (0.47) CA2CA1CA7CYP2D6CTSK
SCHEMBL56783 0.81 CA1 (0.53) CA2CA1CA7CYP2D6CTSK
SCHEMBL24427425 0.81 CA1 (0.53) CA2CA1CA7CYP2D6CTSK
SCHEMBL3389057 0.81 CA1 (0.49) CA2CA1CA7CYP2D6CTSK
SCHEMBL56671 0.81 CA1 (0.53) CA2CA1CA7CYP2D6CTSK
SCHEMBL4574028 0.81 CA1 (0.53) CA2CA1CA7CYP2D6CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540137-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2026-02-03 — — US disclosed
US-20240300947-A1 N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-09-12 — — US disclosed
US-12024514-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-07-02 — — US disclosed
CN-113166143-B N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions and methods 舒万诺知识产权公司 2024-06-04 — — CN disclosed
EP-3887369-B1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-05-08 — — EP disclosed
US-20210323962-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2021-10-21 — — US disclosed
CN-113166143-A N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods 3M创新有限公司 2021-07-23 — — CN disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 — — EP disclosed
EP-1939213-B1 Novel compounds as inhibitors of hepatitis C virus NS3 serine protease SCHERING CORP (US) 2010-08-25 — — EP disclosed
US-7425576-B2 Compounds as inhibitors of hepatitis C virus NS3 serine protease SCHERING CORPORATION (US) 2008-09-16 — — US disclosed
US-7425576-B2 Compounds as inhibitors of hepatitis C virus NS3 serine protease SCHERING CORPORATION (US) 2008-09-16 — — US disclosed
EP-1939213-A1 Novel compounds as inhibitors of hepatitis C virus NS3 serine protease SCHERING CORPORATION (US) 2008-07-02 — — EP disclosed
US-20070142300-A1 Novel compounds as inhibitors of hepatitis C virus NS3 serine protease MERCK SHARP & DOHME LLC 2007-06-21 — — US disclosed
US-20070142300-A1 Novel compounds as inhibitors of hepatitis C virus NS3 serine protease MERCK SHARP & DOHME LLC 2007-06-21 — — US disclosed
US-7186747-B2 Compounds as inhibitors of hepatitis C virus NS3 serine protease SCHERING CORPORATION (US) 2007-03-06 — — US disclosed
US-7186747-B2 Compounds as inhibitors of hepatitis C virus NS3 serine protease SCHERING CORPORATION (US) 2007-03-06 — — US disclosed
WO-2005087725-A2 NOVEL COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE SCHERING CORPORATION (US) 2005-09-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540137-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IRF3, IFNAR1, IFNG CA2 757/4885CA1 2015/4885CA7 1118/4885
US-20070142300-A1 Novel compounds as inhibitors of hepatitis C virus NS3 serine protease SERPINB1, HAVCR2, HPN CA2 4115/4885CA1 3693/4885CA7 3889/4885
US-20240300947-A1 N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods IFNG, IFNAR1, IRF3 CA2 4002/4885CA1 3992/4885CA7 3374/4885
US-20210323962-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS IFNG, IFNAR1, IRF3 CA2 4408/4885CA1 4661/4885CA7 4044/4885
US-12024514-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IFNG, IFNAR1, IRF3 CA2 4408/4885CA1 4661/4885CA7 4044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.